Dialyzability and Pharmacokinetics of ASP2151 Following Single Oral Dosing in Hemodialysis Patients
Phase 1
Completed
- Conditions
- Hemodialysis Patients
- Registration Number
- JPRN-jRCT2080224180
- Lead Sponsor
- Maruho Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Hemodialysis patients
Exclusion Criteria
- Patients who have significant cardiac, hepatic, pulmonary, blood disease considered inappropriate for participation in clinical trials
- Patients with Hepatitis B virus, hepatitis C virus or HIV virus infection
- Patients who have an Hb value <9 g/dL at screening
- Patients with a history of gastrointestinal surgical operation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pharmacokinetics<br>Pharmacokinetics<br>Plasma concentration of ASP2151
- Secondary Outcome Measures
Name Time Method safety<br>Safety assessment<br>Subjective, Objective assessment, Vital sings, Laboratory tests